Sapience Therapeutics, Inc.

Next week, we are looking forward to participating at the 4th Annual Needham & Company Private Biotech Company Virtual 1x1 Forum and engaging with investors in one-on-one meetings. Learn more here: https://lnkd.in/gcNF-J6c #Needham24 #Biotech #Oncology #DrugDevelopment

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. In 2024, CRC is expected to cause more than 53,000 deaths. Sapience Therapeutics, Inc.’s first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. We are pleased to announce that we have begun enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Learn more about the ST316 study here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

With a favorable safety and tolerability profile and robust pre-clinical data, Sapience Therapeutics, Inc. is committed to maximizing the potential of ST316 in colorectal cancer in various therapeutic combinations across multiple lines of treatment. We are excited to have enrolled the first patient in the Phase 2 expansion study and look forward to its continued recruitment. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

#BreakingNews: The first patient has been enrolled in our Phase 2 expansion study evaluating ST316, our first-in-class antagonist of β-catenin (NCT05848739). ST316 selectively shuts down the Wnt/β-catenin signaling pathway in tumor cells but not in normal cells, allowing for anti-cancer activity without the toxicity related to broad inhibition of this pathway. The Wnt/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in our Phase 2 expansion study. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

Next week, we are looking forward to participating in the UBS Biotechnology Private Company Virtual Symposium and engaging with investors in one-on-one meetings. More info here: https://lnkd.in/gmxfGj5a #UBSBiotechSymposium #Biotech #DrugDiscovery #UBSBiotechSymposium

Being a CMO is a pivotal role that demands leadership, strategic vision, and adaptability. Abi Vainstein-Haras, MD, our CMO, sat down with Chief Medical Officer 360º to discuss the evolving responsibilities of this position. In this interview, Dr. Vainstein-Haras shares valuable tips for new CMOs on transitioning from academia to industry, leading clinical trials, and making an impactful first impression. Read more here: https://lnkd.in/gwS3Mdpv #CMO #ChiefMedicalOfficer #Biotech

Each year, on the third Wednesday of July, the National Brain Tumor Society sponsors #GBMday to recognize the impact of this devastating disease and highlight the national need to advance research, raise awareness, and take action to ultimately cure #glioblastoma. At Sapience Therapeutics, Inc., our Phase 2 study of ST101 is being tested in three cohorts of patients with recurrent and newly diagnosed GBM. We are committed to advancing therapies for patients with this complex, treatment-resistant, and deadliest form of #braincancer. Learn more about GBM here: https://braintumor.org/   #Biotechnology #Oncology

We are pleased to announce that patient enrollment is complete in the Phase 1 portion of our ST316 Phase 1-2 clinical study! Recruitment of the Phase 2 expansion portion will begin in the coming weeks.   ST316 selectively targets the WNT/β-catenin signaling pathway in tumor cells but not in normal cells, reducing the toxicity related to inhibition of this pathway. The WNT/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in Phase 2. We are incredibly proud of the execution by our clinical team in achieving this milestone according to planned timelines. We send heartfelt thanks for the contribution of all participants in this study and the support of our clinical collaborators at each site. #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

We are pleased to announce that patient enrollment is complete in the Phase 1 portion of our ST316 Phase 1-2 clinical study! Recruitment of the Phase 2 expansion portion will begin in the coming weeks.   ST316 selectively targets the WNT/β-catenin signaling pathway in tumor cells but not in normal cells, reducing the toxicity related to inhibition of this pathway. The WNT/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in Phase 2. We are incredibly proud of the execution by our clinical team in achieving this milestone according to planned timelines. We send heartfelt thanks for the contribution of all participants in this study and the support of our clinical collaborators at each site. #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

#ASCO24 is a wrap! Thank you to the meeting organizers for recognizing Sapience's exciting science and providing a broad platform to share our ST101 clinical results in GBM. We enjoyed interacting with industry colleagues, clinical investigators, and patient groups, and it was an honor for our data to be accepted as an oral presentation. #ASCO24 #biotech #GBM